MCID: MCR004
MIFTS: 49

Macroglobulinemia

Categories: Immune diseases, Metabolic diseases

Aliases & Classifications for Macroglobulinemia

MalaCards integrated aliases for Macroglobulinemia:

Name: Macroglobulinemia 12 74 15 17
Waldenstrom Macroglobulinemia 71
Primary Macroglobulinemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9080
UMLS 71 C0024419

Summaries for Macroglobulinemia

MalaCards based summary : Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to waldenstroem's macroglobulinemia and lymphoplasmacytic lymphoma. An important gene associated with Macroglobulinemia is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lenograstim and rituximab have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is... more...

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 562)
# Related Disease Score Top Affiliating Genes
1 waldenstroem's macroglobulinemia 33.5 TNFSF13B SYK SDC1 MYD88 CXCR4 CD40LG
2 lymphoplasmacytic lymphoma 33.3 PAX5 MYD88 CXCR4 CXCL12 CD40LG BTK
3 monoclonal gammopathy of uncertain significance 32.2 SDC1 MYD88 IL6 CD40LG CD27
4 purpura 31.0 TNFSF13B IL6 CD40LG
5 cryoglobulinemia 30.9 TNFSF13B IL6 CD40LG CD27
6 marginal zone b-cell lymphoma 30.7 SDC1 PAX5 MYD88 CD40LG BTK
7 peripheral nervous system disease 30.7 TP53 IL6 CD40LG AKT1
8 retinal vein occlusion 30.6 IL6 CXCL12 CD40LG
9 exanthem 30.5 IL6 CD40LG AKT1
10 polyclonal hypergammaglobulinemia 30.5 TNFSF13B IL6 CD40LG
11 neutropenia 30.5 TP53 IL6 CXCR4 CD40LG
12 splenic marginal zone lymphoma 30.4 SYK SDC1 PAX5 BTK
13 anemia, autoimmune hemolytic 30.2 TNFSF13B TNFRSF13B CD52 CD40LG
14 monoclonal paraproteinemia 30.2 SDC1 PAX5 CD40LG
15 bacterial infectious disease 30.2 MYD88 IL6 CD40LG BTK
16 meningitis 30.1 IL6 CXCL12 CD40LG BTK
17 plasmacytoma 30.1 PAX5 IL6 CXCL12 CD27 AKT1
18 cll/sll 30.0 TP53 PAX5 BTK
19 primary agammaglobulinemia 30.0 TNFRSF13C TNFRSF13B
20 plasma cell neoplasm 30.0 TP53 SDC1 PAX5 IL6 CD40LG
21 toxoplasmosis 30.0 MYD88 IL6 CD40LG
22 follicular lymphoma 29.9 TNFRSF13C SYK PAX5 CD27
23 severe combined immunodeficiency 29.9 IL6 CXCR4 CXCL12 CD70 CD27
24 pneumocystosis 29.9 IL6 CD52 CD40LG
25 interstitial lung disease 29.9 TNFRSF13B IL6 CXCL12 CD40LG
26 myelofibrosis 29.9 TP53 CXCR4 CXCL12 CD40LG
27 prostatitis 29.8 TP53 IL6 CXCR4
28 chickenpox 29.7 IL6 CD40LG CD27
29 myelodysplastic syndrome 29.7 TP53 MYD88 IL6 CXCR4 CXCL12 BTK
30 agammaglobulinemia, x-linked 29.7 SYK CXCR4 CXCL12 CD40LG BTK
31 b-cell lymphoma 29.7 TP53 TNFSF13B TNFRSF13C SYK PRKCB PAX5
32 thrombocytopenia due to platelet alloimmunization 29.7 TNFSF13B TNFRSF13B SYK CD52 CD40LG
33 thrombocytopenia 29.6 TNFSF13B TNFRSF13C TNFRSF13B SYK PAX5 IL6
34 hepatitis b 29.6 TP53 MYD88 IL6 AKT1
35 burkitt lymphoma 29.5 TP53 TNFSF13B PAX5 IL6 CD40LG AKT1
36 lymphoma 29.5 TP53 TNFSF13B PAX5 MYD88 IL6 CXCR4
37 leukemia, acute myeloid 29.5 TP53 SYK PAX5 IL6 CXCR4 CXCL12
38 autoimmune disease 29.5 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK IL6
39 respiratory failure 29.5 TNFRSF13B SDC1 IL6 CD40LG
40 cryptococcal meningitis 29.5 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B
41 diffuse large b-cell lymphoma 29.4 TP53 SYK SDC1 PAX5 MYD88 IL6
42 peripheral t-cell lymphoma 29.3 TP53 SYK PAX5 CXCR4 AKT1
43 leukemia, acute lymphoblastic 29.3 TP53 SYK PAX5 CXCR4 CXCL12 CD40LG
44 lymphoma, mucosa-associated lymphoid type 29.3 TP53 TNFSF13B TNFRSF13C SDC1 PAX5 MYD88
45 glioblastoma multiforme 29.1 TP53 PRKCB IL6 CXCR4 CXCL12 AKT1
46 mature b-cell neoplasm 29.0 TP53 SDC1 PAX5 IL6 CD40LG AKT1
47 rheumatoid arthritis 29.0 TNFSF13B TNFRSF13C SYK IL6 CXCR4 CXCL12
48 mantle cell lymphoma 29.0 TP53 SYK PAX5 IL6 CXCR4 CD52
49 immunoglobulin alpha deficiency 28.8 TNFSF13B TNFRSF13C TNFRSF13B CD40LG CD27 BTK
50 central nervous system lymphoma 28.5 TP53 TNFSF13B TNFRSF13C PAX5 MYD88 IL6

Graphical network of the top 20 diseases related to Macroglobulinemia:



Diseases related to Macroglobulinemia

Symptoms & Phenotypes for Macroglobulinemia

MGI Mouse Phenotypes related to Macroglobulinemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.32 AKT1 BTK CD27 CD40LG CD70 CXCL12
2 immune system MP:0005387 10.23 AKT1 BTK CD27 CD40LG CD70 CXCL12
3 cellular MP:0005384 10.21 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
4 cardiovascular system MP:0005385 10.2 AKT1 CD40LG CXCL12 CXCR4 IL6 MYD88
5 homeostasis/metabolism MP:0005376 10.13 AKT1 BTK CD40LG CXCR4 IL6 MYD88
6 endocrine/exocrine gland MP:0005379 10.06 AKT1 CD40LG CXCR4 IL6 MYD88 SDC1
7 neoplasm MP:0002006 9.81 AKT1 BTK CXCR4 IL6 MYD88 PAX5
8 nervous system MP:0003631 9.7 AKT1 CD40LG CXCL12 CXCR4 IL6 MYD88
9 reproductive system MP:0005389 9.32 AKT1 CD40LG CXCL12 CXCR4 IL6 MYD88

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 330)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
rituximab Approved Phase 4 174722-31-7 10201696
3
leucovorin Approved Phase 4 58-05-9 6006 143
4
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12 Hormones Phase 4
13 Immunologic Factors Phase 4
14 Antineoplastic Agents, Hormonal Phase 4
15 Hormone Antagonists Phase 4
16 Antiemetics Phase 4
17 Immunosuppressive Agents Phase 4
18 Gastrointestinal Agents Phase 4
19 glucocorticoids Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Antirheumatic Agents Phase 4
22 Antineoplastic Agents, Immunological Phase 4
23 Antimetabolites Phase 4
24 Immunoglobulins, Intravenous Phase 4
25 Dermatologic Agents Phase 4
26 Vitamin B Complex Phase 4
27 Folate Phase 4
28 Vitamin B9 Phase 4
29 Folic Acid Antagonists Phase 4
30 Methylprednisolone Acetate Phase 4
31 Neuroprotective Agents Phase 4
32 Protective Agents Phase 4
33
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
34
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
35
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
36
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
37 Orange Approved Phase 3
38
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
39
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
40
Chlorambucil Approved Phase 3 305-03-3 2708
41
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
42
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
43
Ondansetron Approved Phase 3 99614-02-5 4595
44
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
45
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
46
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
47
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
48
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
49
Tazobactam Approved Phase 3 89786-04-9 123630
50
Vancomycin Approved Phase 3 1404-90-6 14969 441141

Interventional clinical trials:

(show top 50) (show all 498)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China Unknown status NCT02844322 Phase 4 Bortezomib;Rituximab
2 Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844361 Phase 4
3 The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844309 Phase 4 Thalidomide
4 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia Recruiting NCT04042376 Phase 4 Ibrutinib
6 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
7 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
9 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
10 iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia Completed NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
11 A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
12 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
13 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
14 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
15 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
16 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
17 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
18 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
19 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
20 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
21 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
22 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
23 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
24 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
25 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
26 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
27 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
28 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
29 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
30 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
31 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
32 A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
33 Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Active, not recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
34 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 PCI-32765 (Ibrutinib)
35 Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia Not yet recruiting NCT04061512 Phase 2, Phase 3 Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
36 Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1) Not yet recruiting NCT04263480 Phase 3 Carfilzomib + Ibrutinib;Ibrutinib
37 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
38 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
39 A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
40 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
41 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
42 Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
43 Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas Unknown status NCT00927797 Phase 2 Cyclophosphamide, Pentostatin, Rituximab
44 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
45 Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
46 Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
47 Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL Unknown status NCT01016990 Phase 2 valproic acid
48 Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
49 A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
50 Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Completed NCT01416428 Phase 1, Phase 2 oprozomib

Search NIH Clinical Center for Macroglobulinemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorambucil
Cyclophosphamide
Ibrutinib
Thalidomide

Genetic Tests for Macroglobulinemia

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

40
B Cells, Bone, Bone Marrow, T Cells, Liver, Testes, Myeloid

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

(show top 50) (show all 3370)
# Title Authors PMID Year
1
Total Knee Periprosthetic Joint Infection in the Setting of Hematologic Malignancy: Considerations for Management. 61
32514420 2020
2
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. 61
32284437 2020
3
Subtype Distribution, Clinical Features, and Survival in B-cell Chronic Lymphoproliferative Disorders in China: A Review of 1592 Cases. 61
32220598 2020
4
The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma. 61
32533097 2020
5
Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. 61
32535708 2020
6
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. 61
32564775 2020
7
Tirabrutinib: First Approval. 61
32382949 2020
8
Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience. 61
32567936 2020
9
Diagnosis of a difficult to differentiate case of early-onset hyperviscosity syndrome caused by IgM type multiple myeloma: a case report. 61
32572827 2020
10
Non-Hodgkin's Lymphoma of the Anterior Maxilla Mimicking a Chronic Apical Abscess. 61
32565334 2020
11
Neoplastic Cutaneous Infiltration by Lymphoplasmacytic Lymphoma in a Patient with Waldenström's Macroglobulinemia. 61
32553661 2020
12
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. 61
31992103 2020
13
Waldenstrom's macroglobulinemia in the era of immunotherapy. 61
31960730 2020
14
Clinical Reasoning: Multifocal neuropathies in a patient with Waldenstrom macroglobulinemia and prior borreliosis. 61
32527969 2020
15
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. 61
32558607 2020
16
TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation. 61
32574366 2020
17
Extensive multifocal and pleomorphic pulmonary lesions in Waldenström macroglobulinemia: A case report. 61
32548160 2020
18
Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in Waldenström macroglobulinemia. 61
32577844 2020
19
Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features. 61
32457988 2020
20
Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. 61
32481736 2020
21
High plasma D-dimer level is a poor prognostic factor for patients with waldenström macroglobulinemia. 61
31928271 2020
22
Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. 61
32424672 2020
23
Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia. 61
32532610 2020
24
Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia. 61
31858758 2020
25
Paraneoplastic pemphigus associated with Waldenström's macroglobulinemia. 61
32103535 2020
26
New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM. 61
32260318 2020
27
Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With Waldenström Macroglobulinemia: Response to Direct-acting Antiviral Therapy. 61
32033929 2020
28
Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia. 61
31724890 2020
29
An unusual case of cutaneous Waldenstrom macroglobulinemia with the MYD88 L265P mutation. 61
32335928 2020
30
Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report. 61
32323419 2020
31
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. 61
32083995 2020
32
Chylothorax as an Initial Manifestation of Waldenström macroglobulinemia. 61
32382468 2020
33
Waldenstrom's Macroglobulinemia: A case report. 61
32509689 2020
34
Lymphoplasmacytic lymphoma infiltrating both lacrimal glands in a patient with Waldenström's macroglobulinemia. 61
32016162 2020
35
Spectral-domain optical coherence tomography of retinal vessels in Waldenström's macroglobulinemia. 61
31423759 2020
36
Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. 61
31814157 2020
37
Mixed Lytic and Blastic Bone Lesions as a Presenting Feature of Waldenström Macroglobulinemia: Case Report and Review of the Literature. 61
31899159 2020
38
Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience. 61
31852014 2020
39
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. 61
31866281 2020
40
Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia. 61
31544563 2020
41
Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia. 61
31866282 2020
42
Droplet Digital PCR Assay for MYD88L265P : Clinical Applications in Waldenström Macroglobulinemia. 61
32072140 2020
43
Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. 61
32006301 2020
44
A Case of a Lymphoplasmacytic Lymphoma with Trisomy 12 in the Lymphoid Population and Deletion 13q in the Unstimulated Cell Culture. 61
32161185 2020
45
JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. 61
31432632 2020
46
Management of intraoral bleeding in patients with Waldenström macroglobulinemia: A protocol proposal. 61
31793024 2020
47
HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom's Macroglobulinemia. 61
32274227 2020
48
Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. 61
32158088 2020
49
Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. 61
32509586 2020
50
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. 61
31935288 2020

Variations for Macroglobulinemia

Expression for Macroglobulinemia

Search GEO for disease gene expression data for Macroglobulinemia.

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 TP53 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK
2
Show member pathways
13.77 TP53 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB
3
Show member pathways
13.62 TP53 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB
4
Show member pathways
13.52 TP53 TNFSF13B TNFRSF17 TNFRSF13C IL6 CXCR4
5
Show member pathways
13.29 TP53 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK
6
Show member pathways
13.05 TP53 SYK PRKCB IL6 CXCL12 BTK
7
Show member pathways
13.04 TP53 SYK PRKCB MYD88 IL6 BTK
8
Show member pathways
13.04 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB IL6
9
Show member pathways
12.92 TP53 SYK PRKCB MYD88 IL6 CXCR4
10
Show member pathways
12.84 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B IL6 CXCR4
11 12.83 TP53 PRKCB IL6 CXCR4 CXCL12 AKT1
12
Show member pathways
12.83 TP53 SYK PRKCB MYD88 IL6 BTK
13
Show member pathways
12.82 SYK CXCR4 CXCL12 BTK AKT1
14 12.79 TP53 SYK MYD88 IL6 AKT1
15
Show member pathways
12.72 TP53 SYK PRKCB BTK AKT1
16
Show member pathways
12.7 TP53 MYD88 CD70 CD27 AKT1
17
Show member pathways
12.7 TNFSF13B TNFRSF13C PRKCB MYD88 IL6 CXCL12
18
Show member pathways
12.67 TP53 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK
19
Show member pathways
12.65 TP53 PRKCB CXCR4 CD70 CD40LG CD27
20
Show member pathways
12.55 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B MYD88 CD70
21 12.49 TNFSF13B TNFRSF17 SYK PAX5 MYD88 CXCR4
22
Show member pathways
12.43 SYK PRKCB BTK AKT1
23
Show member pathways
12.43 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK AKT1
24
Show member pathways
12.4 SYK PRKCB BTK AKT1
25
Show member pathways
12.38 SYK PRKCB CD40LG AKT1
26 12.33 TP53 TNFRSF13C IL6 AKT1
27
Show member pathways
12.31 TP53 SDC1 MYD88 IL6 AKT1
28 12.29 TP53 SDC1 PRKCB AKT1
29
Show member pathways
12.26 TP53 PRKCB IL6 CXCL12 AKT1
30
Show member pathways
12.25 PRKCB MYD88 CD40LG AKT1
31 12.23 SYK MYD88 IL6 AKT1
32
Show member pathways
12.22 SYK MYD88 IL6 BTK AKT1
33
Show member pathways
12.16 SYK PRKCB BTK AKT1
34
Show member pathways
12.07 SYK PRKCB BTK AKT1
35 11.9 SYK PRKCB MYD88 BTK
36 11.79 TP53 IL6 AKT1
37
Show member pathways
11.76 TNFSF13B TNFRSF17 TNFRSF13B CD40LG
38 11.75 CXCR4 CXCL12 AKT1
39
Show member pathways
11.71 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B CD70 CD40LG
40
Show member pathways
11.69 TP53 MYD88 AKT1
41 11.68 PRKCB MYD88 AKT1
42 11.67 CXCR4 CXCL12 AKT1
43 11.57 SDC1 MYD88 IL6 CD40LG
44 11.57 TNFSF13B TNFRSF13C SYK PRKCB MYD88 CXCL12
45 11.55 TP53 IL6 AKT1
46 11.51 IL6 BTK AKT1
47 11.42 TNFRSF13C TNFRSF13B CD40LG BTK
48 11.39 PRKCB MYD88 IL6
49 11.29 TNFRSF13B CXCR4 CXCL12
50 11.02 TNFSF13B IL6 CXCL12 CD70 CD40LG BTK

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.16 TP53 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK
2 protein-containing complex GO:0032991 9.63 TP53 SYK SDC1 MYD88 CXCR4 AKT1
3 plasma membrane GO:0005886 9.55 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK STOML2
4 external side of plasma membrane GO:0009897 9.43 TNFRSF13C SDC1 CXCR4 CXCL12 CD40LG CD27

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.18 TNFSF13B TNFRSF17 PRKCB MYD88 IL6 CXCR4
2 negative regulation of apoptotic process GO:0043066 10.03 TP53 MYD88 IL6 CD40LG CD27 AKT1
3 immune response GO:0006955 10.01 TNFSF13B IL6 CXCR4 CXCL12 CD70 CD40LG
4 apoptotic process GO:0006915 9.98 TP53 PRKCB MYD88 CXCR4 CD27 BTK
5 adaptive immune response GO:0002250 9.97 TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB BTK
6 cytokine-mediated signaling pathway GO:0019221 9.95 TP53 SDC1 MYD88 IL6 AKT1
7 inflammatory response GO:0006954 9.88 SDC1 MYD88 IL6 CXCR4 CD40LG AKT1
8 platelet activation GO:0030168 9.83 SYK PRKCB IL6 CD40LG
9 protein import into nucleus GO:0006606 9.81 TP53 SYK AKT1
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 MYD88 IL6 AKT1
11 immune system process GO:0002376 9.76 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 PRKCB MYD88 IL6 CD40LG BTK
13 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.63 MYD88 AKT1
14 B cell homeostasis GO:0001782 9.63 TNFSF13B TNFRSF13C TNFRSF13B
15 positive regulation of mitochondrial membrane potential GO:0010918 9.62 STOML2 AKT1
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 TP53 IL6
17 response to peptidoglycan GO:0032494 9.61 MYD88 IL6
18 telencephalon cell migration GO:0022029 9.6 CXCR4 CXCL12
19 cellular response to molecule of fungal origin GO:0071226 9.59 SYK BTK
20 immunoglobulin secretion GO:0048305 9.58 TNFSF13B CD40LG
21 B cell costimulation GO:0031296 9.58 TNFSF13B TNFRSF13C
22 positive regulation of germinal center formation GO:0002636 9.57 TNFSF13B TNFRSF13C
23 T cell costimulation GO:0031295 9.56 TNFSF13B TNFRSF13C CD40LG AKT1
24 positive regulation of B cell differentiation GO:0045579 9.54 SYK CD27 BTK
25 response to ultrasound GO:1990478 9.51 CXCR4 CXCL12
26 positive regulation of T cell proliferation GO:0042102 9.35 TNFSF13B TNFRSF13C IL6 CD70 CD40LG
27 tumor necrosis factor-mediated signaling pathway GO:0033209 9.23 TP53 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B CD70

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.35 TNFSF13B IL6 CXCL12 CD70 CD40LG
2 tumor necrosis factor receptor binding GO:0005164 9.33 TNFSF13B CD70 CD40LG
3 Toll-like receptor binding GO:0035325 9.26 SYK MYD88
4 signaling receptor binding GO:0005102 9.1 TNFSF13B SYK STOML2 MYD88 CXCL12 CD70

Sources for Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....